Accurate Prediction of Central Conventional Chondrosarcoma Risk and Outcome Using Methylation Profiling: CHROME
Genes, Chromosomes and Cancer · 2026
DOI: 10.1002/gcc.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2026. Verfasst von Sara Cardoso und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Chondrosarcoma, DNA Methylation, Bone Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leiden Center for computational Oncology, H2020 European Research Council, ZonMw.
Abstract (Originalsprache)
Chondrosarcomas are malignant cartilage‐forming bone tumors with heterogeneous behavior, making prognostication and clinical management challenging. Histological grading is the primary tool for predicting clinical outcomes in conventional chondrosarcoma. However, its high interobserver variability limits reliable distinction between low‐ and high‐risk patients, potentially leading to suboptimal clinical management. Given the increasing use of DNA methylation profiling as a valuable tool in surgical pathology for tumor classification, we investigated its prognostic value in central conventional chondrosarcoma. We generated methylation data from 69 primary central conventional chondrosarcomas profiled with Illumina's Human MethylationEPIC Array (850 k sites), and identified methylation sites individually linked to patient outcome. A LASSO Cox regression model was applied to these methylation sites to identify an optimal set of eight informative sites. With the regression coefficients of these methylation sites, we constructed a risk score that predicts central conventional Chondrosarcoma Risk Outcome from Methylation (CHROME). CHROME stratifies patients into High or Low risk groups for disease recurrence, onset of metastasis and disease‐specific mortality. Survival analysis in an independent validation cohort ( n = 68) demonstrated strong discriminatory performance of CHROME, with complete separation of outcomes and no adverse events observed in the Low risk group. Overview of the clinico‐pathological information showed that a low grade (ACT/G1) case with an event was correctly assigned to the High risk group, while nine high grade cases without events were classified as Low risk . CHROME provides accurate risk stratification in central conventional chondrosarcoma and may represent a valuable tool for improving its prognostication and clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
- Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, the Netherlands.
- Bone Tumor Reference Center at the Institute of Pathology, University Hospital Basel and University Basel, Basel, Switzerland.
- Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
- Basel Research Centre for Child Health, Basel, Switzerland.
ORCID-Profile: Sara Cardoso, Baptiste Ameline, Sanne Venneker, Anne-Marie Cleton-Jansen, Jon Brugger, Michiel A J van de Sande, Felix Haglund de Flon, Noel F C C de Miranda, Judith V M G Bovée
Förderung
- Leiden Center for computational Oncology
- H2020 European Research Council
- ZonMw
- Bone Cancer Research Trust
Zitieren
APA
Cardoso, S., Ameline, B., Venneker, S., Meijer, D. M., Erdem, Z. B., Ruano, D., van den Akker, B. E., Cleton-Jansen, A. M., Brugger, J., Briaire-de Bruijn, I. H., Scholte, C. H. J., van de Sande, M. A. J., de Flon, F. H., Baumhoer, D., de Miranda, N. F. C. C., & Bovée, J. V. M. G. (2026). Accurate Prediction of Central Conventional Chondrosarcoma Risk and Outcome Using Methylation Profiling: CHROME. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70160
Vancouver
Cardoso S, Ameline B, Venneker S, Meijer DM, Erdem ZB, Ruano D, et al. Accurate Prediction of Central Conventional Chondrosarcoma Risk and Outcome Using Methylation Profiling: CHROME. Genes, Chromosomes and Cancer. 2026. doi:10.1002/gcc.70160
BibTeX
@article{Cardoso2026,
author = {Cardoso, Sara and Ameline, Baptiste and Venneker, Sanne and Meijer, Debora M and Erdem, Zeynep B and Ruano, Dina and van den Akker, Brendy E and Cleton-Jansen, Anne-Marie and Brugger, Jon and Briaire-de Bruijn, Inge H and Scholte, Claire H J and van de Sande, Michiel A J and de Flon, Felix Haglund and Baumhoer, Daniel and de Miranda, Noel F C C and Bovée, Judith V M G},
title = {Accurate Prediction of Central Conventional Chondrosarcoma Risk and Outcome Using Methylation Profiling: CHROME},
journal = {Genes, Chromosomes and Cancer},
year = {2026},
doi = {10.1002/gcc.70160}
}
EUVIMED